By Fineline Cube Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that its novel drug candidate HSK42360 has been included in the Support Anti‑tumor drugs R&D for Kids (SPARK) project by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The designated indication is relapsed or progressive glioma carrying the BRAF V600 mutation in pediatric patients.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE / NMPA (China) |
| Program | SPARK (Support Anti‑tumor drugs R&D for Kids) |
| Product | HSK42360 (BRAF V600 inhibitor) |
| Indication | Relapsed/progressive BRAF V600‑mutant pediatric glioma |
| Significance | No approved targeted therapy for this indication in China |
| Drug Class | Brain‑penetrant small molecule inhibitor |
Drug Profile & Mechanism of Action
- Target: BRAF V600 mutation – Key oncogenic driver in glioma and other solid tumors
- Molecule: Brain‑penetrant small molecule inhibitor designed to cross blood‑brain barrier
- Mechanism: Selective inhibition of mutant BRAF kinase activity, blocking MAPK/ERK oncogenic signaling cascade
- Clinical Advantage: CNS penetration addresses unmet need in pediatric brain tumors where standard therapies fail
- Broader Development: Also under evaluation for advanced BRAF V600‑mutant solid tumors in adult populations
Disease Context & Unmet Need
| Factor | Detail |
|---|---|
| Pediatric Glioma | Most common CNS tumor in children |
| BRAF V600 Prevalence | ~15‑20% of pediatric low‑grade gliomas; higher in specific subtypes |
| Current Standard | Surgery, radiation, chemotherapy – limited efficacy in relapsed cases |
| Targeted Therapy Gap | No approved BRAF V600 inhibitor for pediatric glioma in China |
| Prognosis | Poor outcomes for relapsed/progressive disease; urgent need for precision therapeutics |
Strategic Implications
- SPARK Program Benefits:
- Accelerated regulatory pathway with dedicated CDE guidance
- Priority review status for pediatric oncology applications
- Data requirements flexibility enabling faster development timelines
- First‑Mover Position: HSK42360 positioned as potential first‑to‑market BRAF V600 therapy for pediatric glioma in China, capturing orphan drug advantages.
- Pipeline Synergy: Builds on Haisco’s CNS and oncology expertise; adult solid tumor program provides clinical foundation for pediatric expansion.
- Commercial Potential: Addressable market of ~3,000‑5,000 annual pediatric BRAF V600‑mutant glioma cases in China; orphan pricing supports ¥300‑500 million peak revenue potential.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory pathways, clinical development timelines, and commercial expectations for HSK42360. Actual results may differ due to risks including trial failures, safety signals, competitive entry, and reimbursement uncertainties in pediatric oncology.-Fineline Info & Tech